Rhythm Biosciences has clarified inconsistencies in its disclosures around termination events in its underwriting agreement for RHYO options, following an ASX query. The company acknowledged an incomplete initial summary and administrative oversights but confirmed the agreement remains in full effect.
- Underwriting Agreement executed overnight 24-25 February 2026
- Initial 25 February announcement contained incomplete termination event details
- Prospectus on 30 March corrected and expanded termination event disclosures
- Appendix 3B on 2 April mistakenly referenced outdated termination details
- Company confirms compliance with Listing Rule 3.1 and ongoing underwriting validity
Execution and Disclosure Timeline of Underwriting Agreement
Rhythm Biosciences (ASX:RHY) has confirmed its underwriting agreement for the exercise of RHYO options was executed overnight between 24 and 25 February 2026. However, the company’s initial market announcement on 25 February contained an incomplete summary of termination events that govern the agreement. This gap prompted a detailed query from ASX Compliance, which Rhythm has now addressed.
The company explained that the 25 February announcement’s summary of termination events was prepared before the finalisation of the Underwriting Agreement and inadvertently omitted some provisions. The more comprehensive and accurate termination events were subsequently disclosed in the Prospectus released on 30 March 2026, which Rhythm says "supersedes" the earlier announcement’s summary.
Key Differences in Termination Event Disclosures
A notable discrepancy highlighted by ASX was the definition of "market fall" as a termination event. The 25 February announcement referenced falls in the S&P/ASX 300 and Small Ordinaries indices by specific percentages, whereas the executed Underwriting Agreement and Prospectus expanded this to include multiple global indices such as Dow Jones, Nasdaq, FTSE, and Nikkei, with a lower threshold of a 5% fall on two consecutive trading days.
Rhythm maintains that despite these differences in wording and scope, the anticipated impact of the broader indices and share price conditions was not materially different to warrant separate market-sensitive disclosure at the earlier date. Still, the company acknowledged the initial summary was incomplete and committed to improving its disclosure processes to prevent recurrence.
Administrative Oversights and Compliance Assurance
The company admitted that its Appendix 3B filing on 2 April mistakenly reverted to the earlier, inaccurate termination event descriptions due to an administrative oversight, rather than reflecting the corrected details in the Prospectus. Rhythm confirmed the Underwriting Agreement remains fully effective, with a Shortfall Notice issued on 2 April under the agreement’s terms.
Rhythm also reaffirmed compliance with ASX Listing Rule 3.1 on continuous disclosure, citing its internal review and approval processes governed by the company’s Continuous Disclosure Policy. The CEO, David Atkins, signed off on the ASX response, confirming the company’s commitment to transparency and regulatory adherence.
Implications for Investors and Market Transparency
While the disclosure gaps and subsequent clarifications may raise questions about internal controls at Rhythm, the company’s swift engagement with ASX and corrective steps provide some reassurance. This episode underscores the challenges biotech companies face in balancing complex underwriting agreements with timely and accurate market communication, especially amid ongoing commercial milestones such as the recent ColoSTAT® test validation.
Investors should monitor whether Rhythm’s improved disclosure practices hold steady as the company progresses with its commercial and regulatory agenda. The broader market will be watching how such administrative slip-ups might affect investor confidence in a sector where transparency is paramount.
Bottom Line?
Rhythm’s disclosure missteps highlight the need for tighter controls but confirm the underwriting deal’s intact status and regulatory compliance.
Questions in the middle?
- Will Rhythm Biosciences strengthen its disclosure oversight to prevent future lapses?
- How might the expanded termination events affect underwriting risk perceptions among investors?
- Could these disclosure issues influence market confidence ahead of Rhythm’s commercial scaling?